The use of US health insurance data for surveillance of rare disorders: Hereditary hemorrhagic telangiectasia

Genetics in Medicine

Volumn 16, Issue 1, 2014, Pages 33-39

  Grosse, Scott D ^a   Boulet, Sheree L ^b   Grant, Althea M ^a   Hulihan, Mary M ^a   Faughnan, Marie E ^c,d,e  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e HHT Foundation International   (United States)

Author keywords

administrative data; epidemiology; Osler Weber Rendu disease; prevalence

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ANEMIA; ANGIODYSPLASIA; ARTERIOVENOUS MALFORMATION; ARTICLE; BRAIN ARTERIOVENOUS MALFORMATION; DISEASE SURVEILLANCE; EPISTAXIS; FEMALE; HEALTH INSURANCE; HUMAN; ICD-9-CM; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICARE; MIDDLE AGED; NEWBORN; PREDICTIVE VALUE; PREVALENCE; PULMONARY ARTERIOVENOUS FISTULA; RENDU OSLER WEBER DISEASE; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

AGE FACTORS; DATABASES, FACTUAL; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; RARE DISEASES; RISK FACTORS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; UNITED STATES;

EID: 84893581613     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.66     Document Type: Article

References (25)

1. Grosse SD, James AH, Lloyd-Puryear MA, Atrash HK. A public health framework for rare blood disorders. Am J Prev Med 2011;41(6 suppl 4):S319-S323.
2. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000;96:437-442.
3. Grosse SD, Boulet SL, Amendah DD, Oyeku SO. Administrative data sets and health services research on hemoglobinopathies: a review of the literature. Am J Prev Med 2010;38(suppl 4):S557-S567.
4. Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999;245:31-39.
5. Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 2002;19:140-148.
6. McDonald J, Damjanovich K, Millson A, et al. Molecular diagnosis in hereditary hemorrhagic telangiectasia: findings in a series tested simultaneously by sequencing and deletion/duplication analysis. Clin Genet 2011;79:335-344.
7. McDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med 2011;13:607-616.
8. Cottin V, Khouatraa C, Dupuis-Girod S, Cordiera JF. Pulmonary vascular disorders in hereditary hemorrhagic telangiectasia. In: Humbert M, Souza R, Simonneau G (eds). Pulmonary Vascular Disorders, vol. 41. Prog Respir Res. Karger: Basel, 2012:262-275.
9. Bayrak-Toydemir P, McDonald J, Markewitz B, et al. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations. Am J Med Genet A 2006;140:463-470.
10. Letteboer TG, Mager JJ, Snijder RJ, et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 2006;43:371-377.
11. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010;24:203-219.
12. Pierucci P, Lenato GM, Suppressa P, et al. A long diagnostic delay in patients with hereditary haemorrhagic telangiectasia: a questionnaire-based retrospective study. Orphanet J Rare Dis 2012;7:33.
13. Sabbà C, Pasculli G, Suppressa P, et al. Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM 2006;99:327-334.
14. Faughnan ME, Palda VA, Garcia-Tsao G, et al.; HHT Foundation International-Guidelines Working Group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011;48:73-87.
15. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-67.
16. Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum 2009;61:755-763.
17. Amendah DD, Mvundura M, Kavanagh PL, Sprinz PG, Grosse SD. Sickle cell disease-related pediatric medical expenditures in the U.S. Am J Prev Med 2010;38(suppl 4):S550-S556.
18. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333:918-924.
19. Gupta S, Faughnan ME, Bayoumi AM. Embolization for pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia: a decision analysis. Chest 2009;136:849-858.
20. Rozenberg D, Faughnan ME. Prevalence and nature of dyspnea in patients with hemorrhagic hereditary telangiectasia (HHT). Chest 2010; 138:841A.
21. Pisa FE, Verriello L, Deroma L, et al. The accuracy of discharge diagnosis coding for amyotrophic lateral sclerosis in a large teaching hospital. Eur J Epidemiol 2009;24:635-640.
22. Ouyang L, Grosse SD, Kenneson A. Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population. J Child Neurol 2008;23:883-888.
23. Bharatha A, Faughnan ME, Kim H, et al. Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment. Stroke 2012;43:72-78.
24. Bernhardt BA, Zayac C, Trerotola SO, Asch DA, Pyeritz RE. Cost savings through molecular diagnosis for hereditary hemorrhagic telangiectasia. Genet Med 2012;14:604-610.
25. Bernhardt BA, Zayac C, Pyeritz RE. Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia. Genet Med 2011;13:812-820.